BCR::ABL1

About

Gene context: ABL1, BCR

Biomarker Type: Rearrangement

Present: True

Rearrangement Type: Fusion


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (2) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
FDA (1) ABL1 p.T315I, BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
FDA (2) HC (2) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
FDA (3) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
FDA (3) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
FDA (2) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
FDA (2) HC (2) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
FDA (2) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
FDA (2) HC (2) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
FDA (3) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
FDA (3) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
FDA (1) BCR::ABL1 Acute Lymphoid Leukemia Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (1) HC (1) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
FDA (2) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
FDA (1) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab